Schwabe Pharmaceuticals reinvests a significant amount of annual sales in research and development of innovative phytomedicines. Drug development focuses on central nervous system and cardiovascular diseases as well as on respiratory and urological indications.

The research process starts with the screening of new plants. Subsequently, special extracts from the plants are developed. A sophisticated production technology finally leads to a product in which beneficial active principles are enriched.

At the same time, harmful components are eliminated from the extract. The derived plant extracts are thoroughly screened using relevant pharmacological and toxicological models to ensure optimal customer safety.

The efficacy and safety of our products are investigated in clinical trials prior to their introduction into the markets. Such trials are performed and monitored by our own clinical research unit in accordance with the ICH -GCP guidelines.

Schwabe’s clinical research on phytomedicines derived from Ginkgo biloba, Saw Palmetto, Hawthorn and St. John’s Wort, to name but a few, has significantly contributed to the acceptance of science-based phytotherapy in the medical community.

Looking back on the long in-house tradition of such studies, Schwabe Pharmaceuticals may be regarded as the inventor of evidence-based phytomedicine.

Our dedication to proving the efficacy and safety of our phytomedicines through rigid pharmacological and clinical studies is unique. This commitment to research and development has fostered long-term academic and corporate partnerships.